PharmaCyte Biotech, Inc. (PMCB) stock soared 1.40% in the current-market trading session at the price of $2.18 despite no recent updates.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
PMCB is a biotechnology firm that develops and commercializes cellular treatments for diabetes and cancer. The company leverages its proprietary Cell-in-a-Box technology to devise therapies for several cancer-based diseases.
CypCaps Trial Positive Data
On 19th April 2022, PMCB revealed that its capsule material for pancreatic cancer product candidate does not induce any systemic toxicity. The study, conducted by a Contract Research Organization, contained the ISO-compliant testing of sulfate cellulose capsules to seek possible systemic toxicity in animals.
After injecting capsule extract, the mice were monitored for clinical symptoms of toxicity at various timings. The body weight of all animals has recorded following the capsule dosage on the first day and days 3, 7, and 14. At the end of the observation duration, all the mice were examined for potential indications of toxicity.
The investigations disclosed that none of the animals perished or showed any signs of toxicity. Moreover, no alterations in body weight had reported. All animals showed a regular gain in body weight during the observation time.
Chief executive officer of PMCB, Kenneth L. Waggoner, remarked that this milestone marks the completion of another study. This time the investigation assessed the potential toxicity of the capsule material for the CypCaps clinical trial product candidate. The study affirms previous results that the capsule material for the drug is inert.
PMCB Business Updates
Earlier in November 2021, PMCB launched its malignant ascites forum by initiating a clinical study to investigate if its treatment for LAPC can also reduce the assemblage of malignant ascites. In December 2021, the stock announced the results of the DNA sequencing assay of Cytochrome P450. Meanwhile, PharmaCyte completed the three-year time point in its “Master Cell Bank” stability clinical study. In February 2022, the stock delivered comprehensive updates on the status of its IND Application submitted to the U.S. FDA.